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Percutaneous coronary intervention with stenting is the most widely performed procedure for the treatment of
symptomatic coronary disease, and drug-eluting stents (DES) have minimized the limitations of bare-metal
stents (BMS). Nevertheless, there remain serious concerns about late complications such as in-stent restenosis
and late stent thrombosis. Although in-stent restenosis of BMS was considered as a stable condition with an
early peak of intimal hyperplasia, followed by a regression period beyond 1 year, recent studies have reported
that one-third of patients with in-stent restenosis of BMS presented with acute coronary syndrome that is not
regarded as clinically benign. Furthermore, both clinical and histologic studies of DES have demonstrated evi-
dence of continuous neointimal growth during long-term follow-up, which is designated as “late catch-up” phe-
nomenon. Here, we present emerging evidence of de novo neoatherosclerosis based on histology, angioscopy,
and intravascular images that provide a new insight for the mechanism of late stent failure. In-stent neoathero-
sclerosis is an important substrate for late stent failure for both BMS and DES, especially in the extended phase.
In light of the rapid progression in DES, early detection of neoatherosclerosis may be beneficial to improving
long-term outcome of patients with DES implants. (J Am Coll Cardiol 2012;59:2051–7) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.909Percutaneous coronary intervention with stenting is the
most widely performed procedure for the treatment of
symptomatic coronary disease (1), and drug-eluting stents
(DES) have minimized the limitations of bare-metal stents
(BMS). Nevertheless, there remain serious concerns about
late complications such as in-stent restenosis (ISR) and late
stent thrombosis (LST) (2–4). Although ISR of BMS was
considered as a stable condition with an early peak of
intimal hyperplasia, followed by a regression period beyond
1 year (5–8), recent studies have reported that one-third of
patients with ISR of BMS presented with acute coronary
syndrome that is not regarded as clinically benign (4).
Furthermore, both clinical and histologic studies of DES
have demonstrated evidence of continuous neointimal
growth during long-term follow-up, which is designated as
“late catch-up” phenomenon (9,10). Here, we present
emerging evidence of de novo neoatherosclerosis based on
histology, angioscopy, and intravascular images that provide
a new insight for the mechanism of late stent failure.
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2011, accepted October 27, 2011.Late Restenosis With Evolving Neointima
Traditionally, intimal hyperplasia after BMS implantation
has been considered stable, with an early peak between 6
months and 1 year and a late quiescent period thereafter
(5–7). Kimura et al. (5) reported an early peak of intimal
growth, followed by intimal regression with luminal en-
largement in a clinical study with 3-year follow-up by
angiography. A histopathologic study of coronary lesions
treated by percutaneous transluminal coronary angioplasty
postulated maturation of smooth muscle cells and modifi-
cation of extracellular matrix as the possible mechanisms of
late neointimal regression (8). This concept has been con-
firmed by a detailed histologic study of autopsy hearts with
BMS implantation in which it was elucidated that alteration
of proteoglycan contents together with conversion of type
III to type I collagen occur over time, eventually leading to
complete neointimal healing at 2-year follow-up (11).
However, a further longer-term follow-up study demon-
strated a triphasic luminal response after BMS placement
characterized by an early restenosis, an intermediate regres-
sion, and a late luminal re-narrowing likely related to
neoatherosclerosis beyond 4 years (12).
In the DES era, late neointimal growth developed within
DES was documented in several animal studies. In a porcine
model study, long-term inhibition of neointimal hyperplasia
after polymer-based sirolimus-eluting stents (SES) was not
maintained, partly because of drug absence and/or persistent
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quent cellular proliferation (13).
Similarly, another animal study us-
ing polymer-coated paclitaxel-
eluting stents (PES) also reported
late neointimal growth with de-
layed healing and local toxicity due
to high-dose paclitaxel (14). Fur-
thermore, intravascular ultrasound
(IVUS) substudy of the ASPECT
(ASian Paclitaxel-Eluting Stent
Clinical Trial) in humans illustrat-
ed suppression of intimal growth
at 6 months and subsequent late
catch-up at 2-year follow-up af-
ter high-dose nonpolymeric PES
implantation (15). More recently,
the late catch-up in patients with
SES placement was indicated by
the higher rate of late target lesion
revascularization (16). In a serial IVUS study (post-stenting,
6-month, and 2-year IVUS follow-up), intimal hyperplasia
continued to increase beyond 6 months after SES and PES
implantation in spite of the early attenuation of intimal growth
and late luminal narrowing over time (17). The previous
observations consistently supported a later occurrence of DES
ISR that might be explained by delayed healing and persistent
inflammatory process (18,19).
Histologic Evidence of
De Novo Neoatherosclerosis
Early histopathologic studies revealed that neointimal com-
ponents after DES implantation were similar to those in BMS
lesions in that the neointima was mainly composed of prolif-
erative smooth muscle cells with proteoglycans-rich extracel-
lular matrix (11,20,21). Nevertheless, there is emerging evi-
dence suggesting that chronic inflammation and/or incompetent
endothelial function induce late de novo neoatherosclerosis
inside both BMS and DES, which may be an important
mechanism of the late phase ISR or thrombosis. Inoue et al.
(22) reported histology findings of autopsied samples in 19
patients with noncardiac death after implantation of Palmaz-
Schatz coronary stents, suggesting the possibility that peristrut
inflammation evoked by a foreign-body reaction to the metal
corrosion might accelerate new indolent atherosclerotic
changes within the stents (22). Conversely, Hasegawa et al.
(23) analyzed 14 BMS lesions with new restenosis that
developed beyond 5 years and demonstrated that restenotic
tissues retrieved by directional coronary atherectomy were
composed of newly developed atherosclerosis facing the “pre-
viously” healed underlying intima regardless of the presence of
peristrut inflammation (Online Table) (23). It is also intriguing
that 4 samples from the cases presented with acute coronary
syndrome exhibited typical histologic morphologies that re-
Abbreviations
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tomography
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VH  virtual histologysemble vulnerable plaque in native coronary arteries.Nakazawa et al. (24) reviewed autopsy cases from the
CVPath (Gaithersburg, Maryland) stent registry and com-
pared 66 SES lesions with 77 BMS lesions where neoath-
erosclerotic change, including the presence of lipid-laden
foamy macrophages, was more frequently identified in the
SES lesions than in the BMS lesions (35% vs. 10%, p 
0.001). Interestingly, a significant difference in the timing of
neoatherosclerosis development was noted; the earliest ath-
erosclerotic change with foamy macrophage infiltration
began at 4 months after SES implantation, whereas the
same change in BMS lesions occurred beyond 2 years and
remained a rare finding until 4 years (Fig. 1). In addition,
the earliest necrotic core formation began at 9 months, whereas
in BMS it occurred at 5 years. Recently, we reviewed histology
findings in 299 autopsy cases (197 BMS and 209 DES lesions)
(25). The incidence of neoatherosclerosis was greater in DES
lesions (31%) than in BMS lesions (16%), and the median
stent duration with neoatherosclerosis was shorter in DES
compared with BMS (420 days [361 to 683 days] vs. 2,160
days [1,800 to 2,880 days]). Unstable lesions like the thin-cap
fibroatheromas (TCFA) or intimal rupture had shorter im-
plant duration for DES (1.5 0.4 years) compared with BMS
(6.1  1.5 years). These results represent that neoatheroscle-
rosis in DES is more frequent and occurs earlier than in BMS,
likely from different pathogenesis (Fig. 2).
Further, there is a question about the difference in the
induction of neoatherosclerosis among various DES. Cur-
rently, the data are mostly available only in SES and PES,
for which the trend toward more rapid neoatherosclerotic
changes is observed in SES than in PES, although the
frequency of neoatherosclerosis in both DES is higher than
BMS (cumulative incidence up to 6 years: SES 38% vs. PES
24% vs. BMS 10%), indicating that differences of drugs or
polymers may influence on neointimal tissues. The effects of
new generation or developing DES have yet to be investigated.
Figure 1 Different Time Points of the Neoatherosclerosis
Percentage of patients with atherosclerotic change in drug-eluting stent (DES)
versus bare-metal stent (BMS) in relation to duration of implant at autopsy is
depicted (24). Note the atherosclerotic change in sirolimus-eluting stents is
seen in 40% of cases by 9 months; in the BMS, the atherosclerotic change does
not begin to appear until 2 years, and remains a rare finding until 4 years.
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De Novo Neoatherosclerosis
A serial angioscopic study (at baseline, 6 to 12 months, and
4 years) after 26 BMS implantations illustrated the
neointimal changes that varied from early healing response
to atherosclerotic transformation represented as yellow
plaque (26). There was a remarkable increase in the inci-
dence of yellow plaque: from 3 cases (4%) at the first
follow-up to 15 cases (58%) at the second follow-up. Late
luminal narrowing, defined as an increase in percent diam-
eter stenosis between the first and second follow-up, was
significantly greater in segments with yellow plaque than in
those without yellow plaque (18.4% vs. 3.6%, p  0.011),
which indicated that atherosclerotic degeneration inside
BMS may contribute to the late luminal narrowing. By
serial angioscopic examinations, Ueda et al. (27) demon-
strated that BMS at 1 to 4 weeks after implantation were
not yet completely covered by neointima and were often
(45%) accompanied by thrombus. However, BMS at 2 to 5
months were completely covered by neointima and throm-
bus was detected only slightly in 13% of patients. Neointima
over BMS usually covers both stent and yellow plaques
under stent completely; and therefore, thrombus was no
Figure 2 Histological Findings of Neoatherosclerosis
(A) Cross-sectional histology of bare-metal stent (BMS) implanted in the coronary
(100). A large necrotic core (NC) containing cholesterol crystals is identified with
macrophages and is markedly thinned (yellow arrowheads point to thinnest portio
asterisks represent metal struts. (C) Cross-sectional histology of paclitaxel-eluting
(D) High-power image of the box in C (200). A relatively small NC containing cho
by numerous foamy macrophages and is markedly thinned (yellow arrowheads polonger detected on the white and smooth neointima even ifthrombus was detected on the yellow plaque (27). Referring
to DES, an angioscopic study by Higo et al. (28) demon-
strated that SES promote the formation of lipid-rich,
atherosclerotic yellow neointima at 10 months, with intra-
mural thrombi being more frequently detected in newly
formed yellow neointima (Fig. 3).
Although there are no available data to date regarding the
angioscopic findings and histologic correlation in intimal
tissue, angioscopic yellow neointima most likely corre-
sponds to foamy macrophages infiltrating into fibrous cap
and/or underlying lipid accumulation; the intensity of yel-
low likely signifies thickness of fibrous cap and amount of
necrotic core. Ultimately, it is also possible that the angio-
scopic yellow neointima with advanced atherosclerotic de-
generation ruptures and leads to further neointimal progres-
sion as well as to late thrombotic events (29).
Grayscale IVUS and VH-IVUS Findings
of In-Stent Neoatherosclerosis
Virtual histology (VH) intravascular ultrasonography (IVUS) in-
volves spectral analysis for frequency and intensity of the
signals to construct tissue maps by classifying plaque into 4
components (fibrous  green; fibrofatty  light green;
for 7 years antemortem (Movat, 20). (B) High-power image of the box in A
neointima. The fibrous cap overlying the NC is infiltrated by numerous foamy
ich resembles vulnerable plaque encountered in native coronary arteries. The
(PES) implanted in the coronary artery for 4 years antemortem (Movat, 40).
ol crystals is formed around metal struts (asterisk). The fibrous cap is infiltrated
hinnest portion).artery
in the
n), wh
stent
lester
int to tnecrotic core  red; and dense calcium  white) (30).
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neointimal tissue because of the signal interference from
metal struts, there are several reports attempting discrimi-
nation of neointimal tissues by IVUS. A case report de-
scribed calcified neointima on grayscale IVUS 8 years after
BMS deployment (31), and other reports demonstrated plaque
rupture and a flaplike dissection inside a restenotic stent
(32,33). In addition, VH-IVUS has recently been reported to
identify neointimal hyperplasia with unstable morphology that
mimics a TCFA as in native arteries.
Kang et al. (34) reported findings from 70 DES-ISR and
47 BMS-ISR lesions with intimal hyperplasia 50% of the
stent area by VH-IVUS (34). The region of interest was
placed between the luminal border and the inner border of
the struts, and tissue composition was represented as per-
centages of intimal area (Fig. 4). The mean follow-up time
was 43.5 months for BMS lesions and 11.1 months for DES
lesions. In both DES and BMS groups, necrotic core and
dense calcium suggesting in-stent neoatherosclerosis were
greater especially in the lesions with longer implant duration.
Even though VH-IVUS is histologically validated in the
assessment of the compositions of naïve atherosclerotic
plaques with high accuracy (94% for necrotic core and 99%
for dense calcium), it is yet to be validated for use with
in-stent tissues (35). Factoring in the complexity of the
in-stent tissues, the methodology needs to be revisited for
the evaluation of neointimal characteristics.
OCT Findings of In-Stent Neoatherosclerosis
Optical coherence tomography (OCT) is a near-infrared
light-based imaging modality with ultrahigh resolution.
Due to the excellent resolution (10 to 20 m), OCT has
Figure 3 Representative Case of Yellow Neointima Formation O
A 44-year-old man with stable effort angina received percutaneous coronary interve
coronary artery (yellow arrows). Angiographic and angioscopic images immediatel
yellow neointima (grade 2, red arrow) at 12 months.demonstrated its potential capacity to accurately character-ize or evaluate the vascular responses after stent implantation,
albeit histological validation has not been performed as yet.
Habara et al. (35) examined the restenotic lesions 5
years after BMS implantation and found a high incidence
(90.7%) of possible neoatherosclerotic change, defined as
heterogeneous OCT appearance with low-intensity areas,
whereas lesions 1 year after BMS implantation showed
only 17.9% incidence of neoatherosclerosis. Neointimal
disruption, which has analogous morphology of ruptured
fibroatheroma in a native coronary artery, occurred more
frequently in 5-year lesions (18.6%) than in 1-year
lesions (0%).
Gonzalo et al. (36) also reported various OCT patterns of
restenotic tissue after stenting (84% were various DES);
however, the median follow-up time was only 12 months,
too short a time to observe the entire spectrum of neoath-
erosclerosis. In contrast, Takano et al. (37) demonstrated
neointimal OCT characteristics of BMS in early (6
months) and extended late phases (5 years). Neointima
exhibited a homogeneous OCT appearance, and there was a
lack of lipid-laden intima in the early phase. Conversely,
lipid-laden intima, intimal disruption, and luminal throm-
bus formation were more frequently observed in the late
phase when compared with the early phase (67% vs. 0%,
38% vs. 0%, and 52% vs. 5%, respectively; all p  0.05).
Thus, it is reasonable to postulate that neointima within
BMS often undergoes a neoatherosclerotic process during
an extended follow-up period. Notably, the neoatheroscle-
rotic process may promote further luminal narrowing and
may play a possible role in the development of an unstable
substrate in the late phase BMS.
Recent OCT analysis in 50 patients with DES-ISR
ES
with a Cypher drug-eluting stent (DES) in the proximal left anterior descending
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June 5, 2012:2051–7 In-Stent Neoatherosclerosisthe 52% of overall lesions had at least 1 TCFA-containing
neointima, 58% had in-stent neointimal rupture, and 58%
showed intraluminal thrombi (38). Patients presenting with
unstable (vs. stable) angina showed a thinner fibrous cap and
an increasing number of unstable OCT findings, including
TCFA-containing neointima, neointima rupture, and
thrombus (Fig. 5). Compared with DES 20 months
post-implantation (the best cut-off to predict TCFA-
containing neointima), DES 20 months post-implantation
had a higher incidence of TCFA-containing neointima (69%
vs. 33%, p 0.012) and red thrombi (27% vs. 0%, p 0.007).
hese findings suggest that in-stent neoatherosclerosis as-
essed by OCT may be an important mechanism of DES
estenosis, especially late after implantation.
n-Stent Neoatherosclerosis
s Common Mechanism of
ate Restenosis and Stent Thrombosis
o date, several pathologic or procedural risk factors have
een elucidated as indicators of LST: delayed arterial
ealing with incomplete endothelialization, chronic inflam-
ation and hypersensitivity reactions, late malapposition
elated to positive remodeling, ostial and/or bifurcation
Figure 4 Examples of Virtual Histology Intravascular Ultrasono
Neointima at Maximal Percent Intimal Hyperplasia Sit
(A) Six-month follow-up of paclitaxel-eluting stent [percent necrotic core [%NC] 10%
(%NC 28%, %DC 8%); (C) 22-month follow-up of paclitaxel-eluting stent (%NC 39
(E) 57-month follow-up of bare-metal stent (%NC 57%, %DC 15%).tenting, and strut penetration into a necrotic core (10,39–41). besides these factors, the extensive data as reviewed in the
receding text support the importance of in-stent neoath-
rosclerosis as a mechanism of LST after either BMS or
ES implantation. A recent histopathology study con-
ucted by Nakazawa et al. (25) confirmed presence of
eoatherosclerosis in both BMS and DES, with shorter
mplant duration for the latter. Although uncovered struts
s a marker of incomplete endothelialization remain the
rimary cause of DES thrombosis, advanced neoatheroscle-
osis with neointimal rupture is also suggested as another
ontributing factor to very late thrombotic events (25).
This new paradigm appears to be rational as it is
onsistent with recent clinical data. Angioscopic data by
igo et al. (28) reported that SES promoted the formation
f lipid-rich, atherosclerotic yellow neointima at 10 months,
nd intramural thrombi were more prevalent in newly
ormed yellow neointima. Further, Lee et al. (42) demon-
trated that in-stent neointimal rupture was identified by
VUS in 44% of DES lesions (mean follow-up of 33
onths) and 100% of BMS lesions (mean follow-up of 108
onths), indicating that neoatherosclerotic progression
ith intimal rupture was 1 of the mechanisms of very late
tent thrombosis. Although there seem to be different
y Composition of
ent dense calcium [%DC] 2%); (B) 9-month follow-up of paclitaxel-eluting stent
C 20%); (D) 48-month follow-up of bare-metal stent (%NC 40%, %DC 25%); andgraph
es
, perc
%, %Diological mechanisms underlying the development of stent
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In-Stent Neoatherosclerosis June 5, 2012:2051–7thrombosis depending upon stent type, it is clear that
neoatherosclerosis plays a role as an important indicator of
LST as well as restenosis in both BMS and DES, but more
importantly in DES, as it occurs much earlier (25). The
shorter interval from implantation to very late stent throm-
bosis in DES than in BMS was consistent with the shorter
time period needed to develop neoatherosclerotic intima
with rupture (41).
The precise mechanisms of neoatherosclerotic develop-
ment in DES remain unknown to date, although incom-
plete endothelial coverage or defective function and altera-
tion of extracellular matrix as an enhancer of atherosclerosis
are suggested through the increased lipid insudation with
monocyte/macrophage activation. The lack of knowledge
regarding the relative roles of progressive intimal hyperpla-
sia, endothelialization, and in-stent atheroma formation,
along with the presence of risk factors, warrants further
Figure 5 OCT Findings of Neointima Inside DES
All white arrows indicate stent struts. Optical coherence tomography (OCT) finding
mid-right coronary artery 65 months earlier and who presented with stable angina:
surrounded by signal-poor, lipidic area (red arrow); and (C) Fibrotic neointima with
DES implantation at mid-left anterior descending artery 60 months earlier and who
(red arrow); (E) TCFA-containing neointima (red arrows) with lipidic tissue; and (F
thickness of fibrous cap was measured at 60 m.investigation on this topic.Conclusions
Emerging evidence suggests in-stent neoatherosclerosis as
an important substrate for both ISR and LST, especially in
the extended phase. In light of the rapid progression in
DES, early detection of neoatherosclerosis may be beneficial
to improving long-term outcome of patients with DES
implants. Although angioscopy and multimodal images
have consistently supported de novo atherosclerotic changes
of neointima for both BMS and DES, the methodologies
should be more validated to clarify the clinical implications.
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